HLK 3002
Alternative Names: HLK-3002Latest Information Update: 02 May 2024
At a glance
- Originator HLK Pharmacin
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Psychiatric disorders
Most Recent Events
- 02 May 2024 HLK Pharmacin intends to file NDA application for Psychiatric disorders in 2025 (HLK Pharmacin pipeline, April 2024)
- 30 Jun 2022 HLK Pharmacin has patent protection for preparation platform technology (HLK Pharmacin pipeline, June 2022)
- 22 Jun 2022 HLK 3002 is available for licensing as of 22 Jun 2022. https://pharmacin.com/#about-us